S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
NASDAQ:ICLR

ICON Public - ICLR Stock Forecast, Price & News

$194.77
-3.72 (-1.87%)
(As of 12/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$194.26
$199.77
50-Day Range
$173.90
$224.80
52-Week Range
$171.43
$313.00
Volume
599,800 shs
Average Volume
568,201 shs
Market Capitalization
$15.85 billion
P/E Ratio
34.60
Dividend Yield
N/A
Price Target
$262.80

ICON Public MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
34.9% Upside
$262.80 Price Target
Short Interest
Healthy
1.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
6.87%
From $10.62 to $11.35 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

136th out of 1,022 stocks

Commercial Physical Research Industry

5th out of 18 stocks

ICLR stock logo

About ICON Public (NASDAQ:ICLR) Stock

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Receive ICLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

ICLR Stock News Headlines

The Critical Minerals Race: U.S. v China
The U.S. is dangerously lacking in critical minerals such as cobalt, lithium, and rare earths needed to maintain our national security. China is aggressively locking up mines and production. But the U.S. is about to strike back with a forceful plan of action to increase domestic production.
Mizuho Securities Reaffirms Their Buy Rating on Icon (ICLR)
ICON Reports Third Quarter 2022 Results
The Critical Minerals Race: U.S. v China
The U.S. is dangerously lacking in critical minerals such as cobalt, lithium, and rare earths needed to maintain our national security. China is aggressively locking up mines and production. But the U.S. is about to strike back with a forceful plan of action to increase domestic production.
Analyst Ratings for Icon
What 6 Analyst Ratings Have To Say About Icon
ICON Releases its 2021 ESG Report
ICON (NASDAQ: ICLR)
See More Headlines
Receive ICLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

ICLR Company Calendar

Last Earnings
11/02/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/28/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ICLR
Employees
38,330
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$262.80
High Stock Price Forecast
$290.00
Low Stock Price Forecast
$215.00
Forecasted Upside/Downside
+34.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$153.18 million
Pretax Margin
6.93%

Debt

Sales & Book Value

Annual Sales
$5.48 billion
Cash Flow
$11.34 per share
Book Value
$99.11 per share

Miscellaneous

Free Float
45,578,000
Market Cap
$15.85 billion
Optionable
Optionable
Beta
1.02

Social Links


Key Executives

  • Dr. Steven A. Cutler MBA (Age 62)
    Ph.D., CEO & Director
    Comp: $3.64M
  • Mr. Brendan Brennan (Age 43)
    Chief Financial Officer
    Comp: $1.63M
  • Jonathan Curtain
    Sr. VP of Corp. & Commercial Fin.
  • Mr. Thomas N. O'Leary
    Chief Information Officer
  • Mr. Diarmaid Cunningham (Age 47)
    Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec.
  • Ms. Niamh Murphy
    Director of Corp. Communications
  • Mr. David Green
    VP of Marketing
  • Mr. Joe Cronin
    Chief HR Officer
  • Mr. Simon Holmes (Age 55)
    Pres of Corp. Investments & Partnerships
  • Ms. Dana Lynn Poff Snr.
    Exec. VP of Program Management













ICLR Stock - Frequently Asked Questions

Should I buy or sell ICON Public stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ICON Public in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ICLR shares.
View ICLR analyst ratings
or view top-rated stocks.

What is ICON Public's stock price forecast for 2023?

11 brokers have issued twelve-month price objectives for ICON Public's stock. Their ICLR share price forecasts range from $215.00 to $290.00. On average, they expect the company's stock price to reach $262.80 in the next twelve months. This suggests a possible upside of 34.9% from the stock's current price.
View analysts price targets for ICLR
or view top-rated stocks among Wall Street analysts.

How have ICLR shares performed in 2022?

ICON Public's stock was trading at $309.70 at the beginning of 2022. Since then, ICLR stock has decreased by 37.1% and is now trading at $194.77.
View the best growth stocks for 2022 here
.

When is ICON Public's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our ICLR earnings forecast
.

How were ICON Public's earnings last quarter?

ICON Public Limited (NASDAQ:ICLR) posted its quarterly earnings results on Wednesday, November, 2nd. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.76 by $0.08. The medical research company earned $1.94 billion during the quarter, compared to analyst estimates of $1.94 billion. ICON Public had a trailing twelve-month return on equity of 10.75% and a net margin of 6.06%.

What guidance has ICON Public issued on next quarter's earnings?

ICON Public issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of $11.65-$11.85 for the period, compared to the consensus EPS estimate of $11.66. The company issued revenue guidance of $7.69 billion-$7.81 billion, compared to the consensus revenue estimate of $7.74 billion.

What is Steve Cutler's approval rating as ICON Public's CEO?

147 employees have rated ICON Public Chief Executive Officer Steve Cutler on Glassdoor.com. Steve Cutler has an approval rating of 63% among the company's employees. This puts Steve Cutler in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ICON Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ICON Public investors own include Pfizer (PFE), Gilead Sciences (GILD), Visa (V), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH), Alibaba Group (BABA), Walt Disney (DIS), Home Depot (HD) and Johnson & Johnson (JNJ).

What is ICON Public's stock symbol?

ICON Public trades on the NASDAQ under the ticker symbol "ICLR."

Who are ICON Public's major shareholders?

ICON Public's stock is owned by a variety of institutional and retail investors. Top institutional investors include CIBC Private Wealth Group LLC (0.34%), Todd Asset Management LLC (0.17%), Kornitzer Capital Management Inc. KS (0.04%), Captrust Financial Advisors (0.03%), Russell Investments Group Ltd. (0.03%) and FDx Advisors Inc. (0.01%).

How do I buy shares of ICON Public?

Shares of ICLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ICON Public's stock price today?

One share of ICLR stock can currently be purchased for approximately $194.77.

How much money does ICON Public make?

ICON Public (NASDAQ:ICLR) has a market capitalization of $15.85 billion and generates $5.48 billion in revenue each year. The medical research company earns $153.18 million in net income (profit) each year or $5.63 on an earnings per share basis.

How many employees does ICON Public have?

The company employs 38,330 workers across the globe.

Does ICON Public have any subsidiaries?
The following companies are subsidiares of ICON Public: Addplan Inc., Aptiv Solutions, Barton & Polansky Associates Inc., Beacon Bioscience Inc., BeijingWits Medical Consulting Ltd., C4 MedSolutions LLC, CHC Group LLC, CRN Holdings LLC, CRN North America LLC, Clinical Research Management, Clinical Resource Network LLC, Complete Healthcare Communications LLC, Complete Publication Solutions LLC, Cross Country Healthcare - Clinical Trial Services, DOCS Global Inc., DOCS Insourcing B.V., DOCS International B.V., DOCS International Belgium N.V., DOCS International Finland Oy, DOCS International France S.A.S., DOCS International Germany GmbH, DOCS International Nordic Countries A/S, DOCS International Poland Sp. z o.o., DOCS International Sweden AB, DOCS International Switzerland GmbH, DOCS International UK Limited, DOCS Italia S.R.L., DOCS Resourcing Limited, DOCS Ukraine LLC, Firecrest Clinical Ltd, Global Pharmaceutical Strategies Group LLC, ICON (LR) Limited, ICON Ankara Klinik Arastirma Dis Ticaret Anonim Sirketi, ICON CRO Malaysia SDN. BHD., ICON Chile Limitada, ICON Clinical International Unlimited Company, ICON Clinical Research (Beijing No.2) Co. Ltd, ICON Clinical Research (Beijing) Co. Ltd, ICON Clinical Research (Canada) Inc., ICON Clinical Research (New Zealand) Limited, ICON Clinical Research (Pte) Limited, ICON Clinical Research (Rus) LLC, ICON Clinical Research (Switzerland) GmbH, ICON Clinical Research (Thailand) Limited, ICON Clinical Research (U.K.) Limited, ICON Clinical Research Austria GmbH, ICON Clinical Research EOOD, ICON Clinical Research España S.L., ICON Clinical Research GmbH, ICON Clinical Research Hong Kong Limited, ICON Clinical Research India Private Limited, ICON Clinical Research Israel Limited, ICON Clinical Research Korea Yuhan Hoesa, ICON Clinical Research Korea Yuhan Hoesa (ICON Clinical Research Korea Ltd.), ICON Clinical Research LLC, ICON Clinical Research Limited, ICON Clinical Research México S.A. de C.V., ICON Clinical Research PTY Limited, ICON Clinical Research Perú S.A., ICON Clinical Research Property Development (Ireland) Limited, ICON Clinical Research S.A., ICON Clinical Research S.R.L., ICON Clinical Research SARL, ICON Clinical Research Services Philippines Inc., ICON Clinical Research Slovakia s.r.o., ICON Clinical Research Sp. z o.o., ICON Clinical Research Taiwan Limited, ICON Clinical Research d.o.o. Beograd, ICON Clinical Research s.r.o., ICON Contracting Solutions Holdings B.V., ICON Development Solutions Limited, ICON Early Phase Services LLC, ICON Global Treasury Limited, ICON Government and Public Health Solutions Inc., ICON Government and Public Health Solutions Inc. (formerly Clinical Research Management (ClinicalRM)), ICON Holdings Clinical Research International Limited, ICON Holdings Unlimited Company, ICON Investments Five Unlimited Company, ICON Investments Four Unlimited Company, ICON Investments Limited, ICON Japan K.K., ICON Klinikai Kutató Korlátolt Felelősségű Társaság, ICON Klinikai Kutató Korlátolt Felelősségű Társaság (ICON Clinical Research Limited Liability Company), ICON Laboratory Services Inc., ICON Pesquisas Clínicas LTDA., ICON US Holdings Inc., Improving Treatments Limited, Ispitivanja ICON d.o.o, Ispitivanja ICON d.o.o (ICON Research Ltd.), MMMM Consulting LLC, MMMM Group LLC, Managed Care Strategic Solutions L.L.C., Mapi Développement SAS, Mapi Group, Mapi Life Sciences Canada Inc., Mapi Life Sciences UK Limited, Mapi Research Trust, Mapi Research Trust*, Mapi SAS, Mapi USA Inc., MeDiNova Investigacion y Desarrollo S.L., MeDiNova Lakeside Clinical Research Limited, MeDiNova Limited, MeDiNova Merc (UK) Limited, MeDiNova Merc Clinical Research (SA) Pty Limited, MeDiNova Research, MedPass International, MediMedia Pharma Solutions, Molecular MD Corp., MolecularMD, Oxford Outcomes Limited, Oxford Outcomes Ltd, PMG Research, PMG Research Inc., PMG Research of Bristol LLC, PMG Research of Charleston LLC, PMG Research of Charlotte LLC, PMG Research of Christie Clinic LLC, PMG Research of Hickory LLC, PMG Research of Raleigh LLC, PMG Research of Rocky Mount LLC, PMG Research of Salisbury LLC, PMG Research of Wilmington LLC, PMG Research of Winston-Salem LLC, PRA Health Sciences, Pacific Research Associates Inc., Prevalere Life Sciences Inc., PriceSpective, Pricespective LLC, PubsHub LLC, Symphony Clinical Research Sp. z o.o., Timaq Medical Imaging, UCT (U.S.) Inc, VSK (Kenilworth) Limited, and Veeda Laboratories Ltd..
Read More
How can I contact ICON Public?

ICON Public's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The official website for the company is www.iconplc.com. The medical research company can be reached via phone at (531) 291-2000 or via fax at 353-1247-6260.

This page (NASDAQ:ICLR) was last updated on 12/9/2022 by MarketBeat.com Staff